ClinicalTrials.gg
Active, not recruitingNCT07530146Updated Oct 15, 2026

Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation

A Phase 3 interventional study of Ketofol and propofol (drug) in The Critically Ill Patient is Requiring Intubation, Septic Shock and Pneumonia, sponsored by Helwan University. Active, not recruiting at 1 site in Egypt. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Helwan University · Phase 3, Interventional, and Treatment

How we know

Updated Oct 15, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Shock, Septic with a site in Egypt — 16 open to participants now, 17 under way, 1 of them phase 3. Shock, Septic · Egypt.

Planned enrollment
14th of 37
70 · median 60
Started
2026
with 7 others
Phase 3
9 of 61
none open now
Primary completion
2026-09
later than 6 of 16 live
Registered
53rd of 61
by date

Among the 61 studies in Shock, Septic with a site in Egypt, this one is the 14th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 6 of the 16 other live ones, and was the 53rd registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

16 of the 61 studies in Shock, Septic with a site in Egypt are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Shock, Septic with a site in Egypt, or all of them as a file.
02

Study summary

The study is a prospective randomized controlled trial comparing the efficacy and safety of propofol-ketamine ("Ketofol") versus propofol monotherapy in geriatric ICU patients. Eligible participants are critically ill elderly patients with a history of cardiac disease who require endotracheal intubation and have not yet received sedation. The investigators focus on a specific population in which geriatric patients have different pharmacokinetics and pharmacodynamics and are more prone to side effects than other populations.

Primary outcome: Incidence of hemodynamic instability (defined as hypotension requiring vasopressors), measured by mean arterial pressure (MAP) 5 minutes after induction

Secondary outcomes include changes in blood pressure and heart rate, incidence of hypotension, vasopressor requirements, sedation depth, pain scores, cumulative sedative and opioid consumption, adverse events, ICU length of stay, and ICU mortality at predefined intervals.

03

Conditions studied

  • The Critically Ill Patient is Requiring Intubation
  • Septic Shock
  • Pneumonia

Keywords

  • ketofol
  • propofol
  • septic shock
  • pneumonia
  • geriatric
  • elderly
  • critical ill
  • ICU patient
  • intubation
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 65 years
  • Admitted to ICU with a diagnosis of infection (sepsis, septic shock, or pneumonia)
  • Known history of cardiac disease (e.g., ischemic heart disease, heart failure, arrhythmias)
  • Requiring endotracheal intubation for airway protection or respiratory failure
  • obtained from patient or legal representative
  • Patient NOT on sedation prior randomization.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to propofol or ketamine
  • Severe hepatic or renal dysfunction ( C, \< 30 mL/min/1.73m²)
  • Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg)
  • Intracranial pathology (e.g., raised intracranial pressure, recent stroke, brain tumor)
  • Ongoing use of other sedative or anesthetic agents within 12 hours prior to intubation
  • Do-not-intubate or do-not-resuscitate orders
  • Participation in another interventional trial within the last 30 days
  • History of Psychosis
  • Severe Organ Dysfunction: Patients with Child-Pugh C hepatic failure
    • Severe hypotension despite vasopressor therapy (systolic blood pressure \< 100 mmHg or diastolic blood pressure \< 70 mmHg)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Ketofol Group (Ketamine + Propofol)

    Patients will take bolus dose of Propofol 0.25 mg/kg + Ketamine 0.25mg/kg If patient NOT sedated and need additional doses will be given another Propofol 0.25 mg/kg + Ketamine 0.25mg/kg IV

    Drug: Ketofol

  • Experimental
    Propofol group ( propofol monotherapy)

    Patients will take Propofol lowest bolus dose of 0.5 mg/kg IV as monotherapy. If patient NOT sedated and need additional doses will be given another dose of 0.25 to 0.5 mg/kg after hemodynamically assessment

    Drug: propofol (drug)

Interventions

  • Patients will take bolus dose of Propofol 0.25 mg/kg + Ketamine 0.25mg/kg If patient NOT sedated and need additional doses will be given another Propofol 0.25 mg/kg + Ketamine 0.25mg/kg IV

  • DrugPropofolStudies of PropofolPropofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Propofol given normal doses for intubation but at reduced and gradual dosing regimen regarding geriatric patient

06

What researchers measure

Primary outcomes

  1. Mean arterial pressure (MAP, mmHg) at 5 minutes

    Mean arterial pressure (MAP, mmHg) at 5 minutes after administration of the induction agent

    Time frame: 5 minutes post induction

Secondary outcomes

  1. Vasopressor escalation within 5 minutes

    Time frame: 5 minutes

  2. Peak norepinephrine dose within 5 minutes

    Time frame: 5 minutes

  3. Systolic blood pressure at 5 minutes after induction

    Systolic blood pressure measured in mmHg

    Time frame: 5 minutes after induction

  4. Diastolic blood pressure at 5 minutes after induction

    Diastolic blood pressure measured in mmHg

    Time frame: 5 minutes after induction

  5. Incidence of hypotension

    Time frame: Post-induction period

  6. Pain intensity score

    using CPOT score

    Time frame: within 24h

  7. Sedation depth (RASS score)

    Time frame: From 30 minutes to 24 hours

  8. Cumulative fentanyl consumption

    Time frame: During the study observation period

  9. Adverse events

    Incidence of Adverse events

    Time frame: During ICU follow-up

  10. All-cause ICU mortality

    Time frame: During ICU stay

07

Study locations

1 site
08

References and documents

Publications

  • Foo TY, Mohd Noor N, Yazid MB, Fauzi MH, Abdull Wahab SF, Ahmad MZ. Ketamine-propofol (Ketofol) for procedural sedation and analgesia in children: a systematic review and meta-analysis. BMC Emerg Med. 2020 Oct 8;20(1):81. doi: 10.1186/s12873-020-00373-4. PubMed 33032544 ↗
  • How to cite this article: Padhi S, Singh GP, Chaturvedi A, Rath GP. Effect of ketofol versus propofol on cerebral oxygenation in patients undergoing transsphenoidal pituitary surgery under total intravenous anesthesia - A randomized control trial. J Neurosci Rural Pract. 2025;16:S52-9. doi: 10.25259/JNRP_138_2025
  • Andolfatto G, Abu-Laban RB, Zed PJ, Staniforth SM, Stackhouse S, Moadebi S, Willman E. Ketamine-propofol combination (ketofol) versus propofol alone for emergency department procedural sedation and analgesia: a randomized double-blind trial. Ann Emerg Med. 2012 Jun;59(6):504-12.e1-2. doi: 10.1016/j.annemergmed.2012.01.017. Epub 2012 Mar 7. PubMed 22401952 ↗
  • El Mourad MB, Shaaban AE, El Sharkawy SI, Afandy ME. Effects of Propofol, Dexmedetomidine, or Ketofol on Respiratory and Hemodynamic Profiles in Cardiac Patients Undergoing Transesophageal Echocardiography: A Prospective Randomized Study. J Cardiothorac Vasc Anesth. 2021 Sep;35(9):2743-2750. doi: 10.1053/j.jvca.2020.11.013. Epub 2020 Nov 10. PubMed 33262033 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in Sep 2026, 4 months.

Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's 4 months is below that.

Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2026
First posted
Apr 15, 2026
StartActual
May 13, 2026
Primary completionActual
Sep 18, 2026was Oct 2026
CompletionEst.
Oct 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Primary completion
Oct 2026→Sep 18, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 2026→Sep 18, 2026 (now actual)
    + 4 other changes: verification date, description, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07530146
Lead sponsor
Helwan University
Responsible party
Mujtaba Alqaisoum (Principal Investigator, Helwan University) — Principal investigator
First posted
Apr 15, 2026
Start date
May 13, 2026
Primary completion
Sep 18, 2026
Completion
Oct 2026 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketofol · Propofol

Start the discussion